Literature DB >> 1003543

Effects of murine tumors on delayed hypersensitivity to dinitrochlorobenzene. I. Description of anergy caused by transplanted tumors.

J M Jessup, M H Cohen, M M Tomaszewski, E L Felix.   

Abstract

In the murine model presented for tumor-associated immune suppression, normal BALB/c mice displayed significant foodpad swelling when sensitized on the flank with 2 mg dinitrochlorobenzene (DNCB) dissolved in dimethyl sulfoxide and challenged in a footpad with 0.05 mg DNCB 10 days later. This reaction in challenged footpads seemed to be a classic delayed hypersensitivity reaction, since it took 24 hours to develop and included an extensive mononuclear infiltrate. The reaction was transmissible from sensitized to normal mice by the transfer of lymphoid cells but not to serum. When sensitized 10 days after tumor inoculation, mice bearing either an allogeneic melanoma or a syngeneic lymphoma or fibrosarcoma did not demonstrate delayed hypersensitivity to DNCB.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1003543     DOI: 10.1093/jnci/57.5.1077

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  4 in total

1.  Macrophages and resistance to tumours. I. Inhibition of delayed-type hypersensitivity reactions by tumour cells and by soluble prducts affecting macrophages.

Authors:  M Nelson; D S Nelson
Journal:  Immunology       Date:  1978-02       Impact factor: 7.397

2.  Influence of tumour carriage on the production of lymphokines affecting macrophage behaviour.

Authors:  L C McIntosh; L M Morrice; Y Udagawa; A W Thomson
Journal:  Immunology       Date:  1986-03       Impact factor: 7.397

3.  Dissociation between tumour resistance and delayed-type hypersensitivity to tumour-associated antigens in the mouse.

Authors:  D C Henderson; D Parker; J L Turk
Journal:  Immunology       Date:  1980-01       Impact factor: 7.397

4.  Enhancement of in vitro prostaglandin E2 production by mouse fibrosarcoma cells after co-culture with various anti-tumour effector cells.

Authors:  F Okada; M Hosokawa; J Hasegawa; Y Kuramitsu; K Nakai; L Yuan; H Lao; H Kobayashi; N Takeichi
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.